Covance, WuXi Abandon Plans To Create Joint Drug Testing Facility In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Just three months after unveiling plans to create a joint venture facility for preclinical drug testing services on China's east coast, the Shanghai-headquartered WuXi PharmaTech and and Princeton, N.J.-based Covance have called off the deal
You may also be interested in...
WuXi Forms JV With PRA To Expand Clinical Services In China
WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.
The Rise Of The Chinese CRO: New Models For An Emerging Player
SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands
The Rise Of The Chinese CRO: New Models For An Emerging Player
SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands